MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

BioMarin Pharmaceutical Inc

Затворен

СекторЗдравеопазване

67.41 -1.43

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

66.74

Максимум

68.31

Ключови измерители

By Trading Economics

Приходи

19M

125M

Продажби

1.6M

747M

P/E

Средно за сектора

31.986

63.778

EPS

0.92

Марж на печалбата

16.719

Служители

3,040

EBITDA

39M

195M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+45.48% upside

Дивиденти

By Dow Jones

Следващи печалби

23.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.6B

14B

Предишно отваряне

68.84

Предишно затваряне

67.41

Настроения в новините

By Acuity

11%

89%

10 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.06.2024 г., 17:41 ч. UTC

Значими двигатели на пазара

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21.08.2024 г., 11:30 ч. UTC

Топ новини

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Сравнение с други в отрасъла

Ценова промяна

BioMarin Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

45.48% нагоре

12-месечна прогноза

Среден 99.39 USD  45.48%

Висок 127 USD

Нисък 70 USD

Според 24 анализатори от Wall Street, предложили 12-месечна ценова цел за BioMarin Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

24 ratings

19

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

67.835 / 71.32Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

10 / 386 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.